3 Consumer Healthcare, Boron Chemical and Riding Gear Stocks With a Strong Future Roadmap: Mankind Pharma, Indo Borax & Chemicals and Studds Accessories
- October 19, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Mankind Pharma Rs 2,275.50, P/E 47.91. Indo Borax Rs 472.40, P/E 27.49. Studds Rs 407.15, P/E 21.92. Closing prices of 14 Oct 2026.
Quick Answer
Consumer healthcare, boron chemical and riding gear stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Indo Borax in boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and Studds in motorcycle helmets and riding accessories sold in India and overseas. FY26 revenue growth was 14.8% at Mankind Pharma, 21.0% at Indo Borax and 8.4% at Studds. P/E stands at 47.91 for Mankind Pharma (industry 37.59), 27.49 for Indo Borax (industry 36.60) and 21.92 for Studds (industry 36.50). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Consumer healthcare, boron chemical and riding gear stocks give investors exposure to medicines, industrial chemicals and safety gear used in daily life. Volumes, pricing and margins decide how much of that demand turns into profit.
Readers comparing consumer healthcare, boron chemical and riding gear stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.
This list covers three consumer healthcare, boron chemical and riding gear stocks: Mankind Pharma for branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Indo Borax & Chemicals for boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and Studds Accessories for motorcycle helmets and riding accessories sold in India and overseas. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Consumer Healthcare, Boron Chemical and Riding Gear Stocks?
Consumer healthcare, boron chemical and riding gear stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Consumer Healthcare, Boron Chemical and Riding Gear Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three consumer healthcare, boron chemical and riding gear stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Mankind Pharma | 2,275.50 | 99,065 | 47.91 | 37.59 | 11.74% | 0.39 |
| Indo Borax & Chemicals | 472.40 | 1,548 | 27.49 | 36.60 | 11.09% | 0.00 |
| Studds Accessories | 407.15 | 1,637 | 21.92 | 36.50 | 15.80% | 0.02 |
Among healthcare, chemicals and consumer stocks, Mankind Pharma trades at a premium to the industry P/E, while Indo Borax and Studds trade at a discount.
Why Do Consumer Healthcare, Boron Chemical and Riding Gear Stocks Have a Strong Roadmap in India?
Consumer healthcare, boron chemical and riding gear stocks have a strong roadmap in India because prescription and consumer health demand, glass and farm chemical use and two-wheeler ownership keep adding volumes for these firms. Three drivers stand out.
- Medicine demand: Doctors prescribe branded formulations across therapies.
- Boron use: Glass, ceramics and farms consume boron chemicals.
- Two-wheeler riders: Safety rules and rising incomes lift helmet demand.
Mankind Pharma: Branded Formulations Anchor the Roadmap
Mankind Pharma’s roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.
Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit was Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.
Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: Q1 FY27 operating margin was 27.42% against 27.06% for FY26, so margin stability is the figure to follow as volumes grow.
Indo Borax & Chemicals: Boron Chemicals Anchor the Roadmap
Indo Borax’s roadmap rests on boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture, with wide industrial usage supporting volumes.
Revenue grew from Rs 178.93 crore in FY22 to Rs 230.89 crore in FY26, a 29.0% rise, and FY26 revenue was 21.0% higher than FY25. FY26 net profit rose 18.3% to Rs 50.27 crore. Over four years, net profit rose from Rs 36.37 crore in FY22 to Rs 50.27 crore. In Q1 FY27, revenue grew 28.9% to Rs 72.92 crore, and net profit rose 59.3% to Rs 16.25 crore. Operating margin was 27.28% in FY26 and 31.78% in Q1 FY27 against 28.43% a year earlier.
Debt to equity is 0.00 and return on equity is 11.09%. FY26 operating cash flow was Rs 87.15 crore against capital expenditure of Rs 0.29 crore. Indo Borax paid a dividend of Rs 1 per share for FY26, a yield of 0.21%. At a P/E of 27.49 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 31.78% against 27.28% for FY26, so margin stability is the figure to follow as volumes grow.
Studds Accessories: Helmets and Riding Gear Build the Next Leg
Studds’ roadmap rests on motorcycle helmets and riding accessories sold in India and overseas, with rising two-wheeler use and safety awareness supporting volumes.
Revenue grew from Rs 467.98 crore in FY22 to Rs 645.75 crore in FY26, a 38.0% rise, and FY26 revenue was 8.4% higher than FY25. FY26 net profit rose 18.7% to Rs 82.65 crore. Over four years, net profit rose from Rs 28.64 crore in FY22 to Rs 82.65 crore. In Q1 FY27, revenue grew 13.8% to Rs 172.92 crore. Operating margin was 21.25% in FY26.
Debt to equity is 0.02 and return on equity is 15.80%. FY26 operating cash flow was Rs 86.42 crore against capital expenditure of Rs 47.04 crore. Studds paid a dividend of Rs 3 per share for FY26, a yield of 0.72%. At a P/E of 21.92 against an industry P/E of 36.50, the stock trades below its industry multiple.
What to watch: The P/E of 21.92 against an industry P/E of 36.50 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Consumer Healthcare, Boron Chemical and Riding Gear Stocks in India: Mankind Pharma vs Indo Borax vs Studds on Key Financials
Among the best consumer healthcare, boron chemical and riding gear stocks in India, Mankind Pharma ranks second on FY26 revenue growth and FY26 operating margin; Indo Borax leads on FY26 revenue growth and FY26 operating margin; Studds leads on return on equity and the lowest P/E. The table puts the numbers side by side.
| Metric | Mankind Pharma | Indo Borax | Studds |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 14,636.43 | 230.89 | 645.75 |
| FY26 revenue growth | 14.8% | 21.0% | 8.4% |
| FY26 net profit (Rs Cr) | 1,938.10 | 50.27 | 82.65 |
| FY26 operating profit margin | 27.06% | 27.28% | 21.25% |
| Q1 FY27 revenue growth (YoY) | 11.7% | 28.9% | 13.8% |
| Return on equity | 11.74% | 11.09% | 15.80% |
| P/E ratio | 47.91 | 27.49 | 21.92 |
| Debt to equity | 0.39 | 0.00 | 0.02 |
| Dividend yield | 0.04% | 0.21% | 0.72% |
| FY26 operating cash flow (Rs Cr) | 3,121.29 | 87.15 | 86.42 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Consumer Healthcare, Boron Chemical and Riding Gear Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen consumer healthcare, boron chemical and riding gear stocks and shortlist consumer healthcare, boron chemical and riding gear stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Consumer Healthcare, Boron Chemical and Riding Gear Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Mankind Pharma, Indo Borax and Studds live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover medicines, boron chemicals and helmets. Mankind Pharma ranks second on FY26 revenue growth and FY26 operating margin; Indo Borax leads on FY26 revenue growth and FY26 operating margin; Studds leads on return on equity and the lowest P/E.
Across consumer healthcare, boron chemical and riding gear stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the consumer healthcare, boron chemical and riding gear stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Consumer Healthcare, Boron Chemical and Riding Gear Stocks
Which are the best consumer healthcare, boron chemical and riding gear stocks in India with a strong roadmap?
Ans. Mankind Pharma, Indo Borax & Chemicals and Studds Accessories stand out for their roadmaps in medicines, boron chemicals and helmets. FY26 revenue growth was 14.8% at Mankind Pharma, 21.0% at Indo Borax and 8.4% at Studds, and return on equity ranges from 11.09% to 15.80%.
Is Mankind Pharma a good stock to buy now?
Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Mankind Pharma, Indo Borax and Studds?
Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 27.49 for Indo Borax (industry 36.60) and 21.92 for Studds (industry 36.50). Only Mankind Pharma trades at or above the industry multiple.
Which of these consumer healthcare, boron chemical and riding gear stocks has the highest return on equity?
Ans. Studds Accessories has the highest return on equity at 15.80%, followed by Mankind Pharma at 11.74% and Indo Borax & Chemicals at 11.09%.
What are the risks of investing in consumer healthcare, boron chemical and riding gear stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Mankind Pharma, Indo Borax and Studds perform in Q1 FY27?
Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. Indo Borax & Chemicals reported revenue of Rs 72.92 crore, up 28.9% year on year, and net profit rose 59.3% to Rs 16.25 crore. Studds Accessories reported revenue of Rs 172.92 crore, up 13.8% year on year.
Do consumer healthcare, boron chemical and riding gear stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.04% for Mankind Pharma, 0.21% for Indo Borax and 0.72% for Studds, based on dividends declared for FY26.
How can I invest in consumer healthcare, boron chemical and riding gear stocks in India?
Ans. You can buy consumer healthcare, boron chemical and riding gear stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.